{"id":20338,"date":"2021-06-01T16:38:25","date_gmt":"2021-06-01T11:08:25","guid":{"rendered":"http:\/\/udaen.info\/?p=20338"},"modified":"2021-06-01T16:38:25","modified_gmt":"2021-06-01T11:08:25","slug":"eli-lillys-drug-approved-by-dcgi-this-antibody-cocktail-therapy-is-effective-in-the-treatment-of-corona","status":"publish","type":"post","link":"https:\/\/udaen.info\/?p=20338","title":{"rendered":"Eli Lilly&#8217;s drug approved by DCGI, this antibody cocktail therapy is effective in the treatment of corona"},"content":{"rendered":"<p>Eli Lilly&#8217;s drug approved by DCGI, this antibody cocktail therapy is effective in the treatment of corona<\/p>\n<p>&nbsp;<\/p>\n<p>Delhi&#8217;s Sir Ganga Ram Hospital has started monoclonal antibody cocktail therapy from Tuesday. The cost of a single dose has been fixed at Rs 59,750. The Drugs Control General of India (DCGI) has approved Eli Lilly for emergency use for moderately symptomatic corona patients. Explain that Eli Lilly is an antibiotic drug used in moderate symptoms of corona patients. It is a drug made by combining the monoclonal antibody bamlanivimab 700 mg and etasevimab 1400 mg (etesevimab 1400 mg).<\/p>\n<p>Giving more information, Luka&#8217;s India Subcontinent Managing Director, Luca Vicini said that we are happy that we have another treatment option for India&#8217;s health sector. Lilly is committed to contributing to the fight against the Corona pandemic in India and around the world. We will continue to assess and evaluate how our current portfolio and ongoing research can benefit coronavirus patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly&#8217;s drug approved by DCGI, this antibody cocktail therapy is effective in the treatment of corona &nbsp; Delhi&#8217;s Sir Ganga Ram Hospital has started monoclonal antibody cocktail therapy from Tuesday. The cost of a single dose has been fixed at Rs 59,750. The Drugs Control General of India (DCGI) has approved Eli Lilly for [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"_monsterinsights_skip_tracking":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[74,12],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/20338"}],"collection":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20338"}],"version-history":[{"count":1,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/20338\/revisions"}],"predecessor-version":[{"id":20339,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/20338\/revisions\/20339"}],"wp:attachment":[{"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20338"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20338"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20338"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}